BioCentury
ARTICLE | Distillery Techniques

Biomarkers

June 27, 2017 4:28 PM UTC

Blood levels of panel of miRNAs could help predict patient responses to antidepressants. In postmortem prefrontal cortex samples from patients, levels of miR-24-3p, miR-146a-5p and miR-146b-5p and miR-425-3p were lower than in unaffected subjects. In 124 patients treated with Cymbalta duloxetine and 61 patients treated with Lexapro escitalopram oxalate or Pamelor nortriptyline hydrochloride, low blood levels of the four miRNAs were associated with low posttreatment disease scores. In another 158 patients treated with Lexapro, blood levels of three of the miRNAs -- miR-24-3p, miR-146a-5p and miR146b-5p -- were associated with low posttreatment disease scores. Next steps include validating the markers in additional cohorts and studying signaling pathways downstream of the miRNAs.

Eli Lilly and Co. and Shionogi & Co. Ltd. market Cymbalta, a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) to treat major depressive disorder (MDD), anxiety and other neurological indications...

BCIQ Company Profiles

McGill University